November 29, 2020
Business News

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

TEL AVIV, Israel & MELBOURNE, Australia–()–Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced a US$20 million financing. The round was led by a syndicate of existing investors including OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund (MRCF) and Ganot Capital.

On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of MGD – an eye condition where the Meibomian glands become dysfunctional, resulting in rapid evaporation of the tear…

Click here to view the original article.

Related Posts

You might also like ...

Canon Medical Continues to Boost Image Quality Across Modalities with Further Expansion of Its AI-Based Image Reconstruction Technology
Canon Medical Launches Premium Auto-Positioning Digital Radiography System for Optimal Productivity and Patient Care
Best Snow Blower Cyber Monday Deals (2020): Best Ariens & Snow Joe Sales Identified by The Consumer Post